Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence | Zendy

Drosos E. Karageorgopoulos | Zendy; Theodoros Kelesidis | Zendy; Iosif Kelesidis | Zendy; Matthew E. Falagas | Zendy

Open Access

Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence

Author(s) -

Drosos E. Karageorgopoulos,

Theodoros Kelesidis,

Iosif Kelesidis,

Matthew E. Falagas

Publication year - 2008

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn165

Subject(s) - tigecycline , acinetobacter , acinetobacter baumannii , medicine , broth microdilution , multiple drug resistance , antibiotics , microbiology and biotechnology , carbapenem , biology , pseudomonas aeruginosa , minimum inhibitory concentration , bacteria , genetics

New antibacterial agents are required for the treatment of infections caused by multidrug-resistant (MDR) Acinetobacter spp. Whether tigecycline constitutes an effective treatment option or not, is not well established. We sought to evaluate the available evidence regarding the microbiological activity and clinical effectiveness of tigecycline for MDR (including the subset of carbapenem-resistant) Acinetobacter spp.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research